As reported by FiercePharma, the U.S. Food and Drug Administration has approved the first fully independent generic version of GlaxoSmithKline’s widely used asthma inhaler, Flovent, marking a significant shift in the competitive landscape for inhaled corticosteroids.
The newly approved product—fluticasone propionate inhalation aerosol—is manufactured by Glenmark Pharmaceuticals and is indicated for long-term asthma control in patients aged four years and older. The drug works by reducing airway inflammation, helping prevent symptoms such as wheezing and shortness of breath rather than treating acute asthma attacks.
While lower-cost versions of Flovent have technically been available for more than two years, those products were “authorized generics” distributed by Prasco Laboratories under an arrangement with GSK. Authorized generics are identical to the branded drug but marketed under a different label and produced by, or with permission from, the brand owner. In contrast, Glenmark’s version is the first FDA-approved generic developed and commercialized independently of GSK.
The approval grants Glenmark a six-month period of generic market exclusivity, during which no other true generic competitors can enter. The company has announced plans to launch the product in the U.S. this month.
The timing is notable, as GSK discontinued its branded Flovent inhalers in early 2024, while continuing to supply authorized generics through Prasco. The arrangement between GSK and Prasco spans more than a decade and has previously included similar agreements for products such as the allergy spray Flonase. Prasco, a privately held company, focuses on bringing brand-name medications to market as authorized generics and positions itself as a leader in that niche.
Industry observers view the FDA’s decision as an important development for asthma care access. Because true generics typically introduce greater pricing pressure than authorized generics, the arrival of Glenmark’s inhaler could help lower costs for patients and payers alike. Commentators on social media have described the approval as a milestone that may meaningfully improve affordability for millions of people managing chronic asthma.
As additional generics are expected to follow after the exclusivity window expires, competition in the fluticasone inhaler market is likely to intensify further later this year.
